Evidence map›Paper›PMID 40313637›Full record

ArticleFrontiers in allergy2025

Identification of an elusive

Keith Wetherby, Joseph Chiao, Emily Faulkner, Yongjian Guo, Shaobin Hou, J Joanna Yu, Jinguo Chen, Lili Wan, H Henry Li

Abstract read
In one paragraph

Article in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Diagnostic delay,Frontiers in allergy · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Keith WetherbyVirant Diagnostics, Inc., Wheaton, MD, United States.
Joseph ChiaoVirant Diagnostics, Inc., Wheaton, MD, United States.
Emily FaulknerVirant Diagnostics, Inc., Wheaton, MD, United States.
Yongjian GuoScitechLink, LLC, Rockville, MD, United States.
Shaobin HouVirant Diagnostics, Inc., Wheaton, MD, United States.
J Joanna YuVirant Diagnostics, Inc., Wheaton, MD, United States.
Jinguo ChenVirant Diagnostics, Inc., Wheaton, MD, United States.
Lili WanVirant Diagnostics, Inc., Wheaton, MD, United States.
H Henry LiVirant Diagnostics, Inc., Wheaton, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hereditary angioedema (HAE) is an autosomal dominant genetic disorder caused by mutations in the C1 esterase inhibitor gene, SERPING1, leading to overproduction of bradykinin and debilitating swelling attacks. Variants in the Methods: We consented and collected whole blood samples from three family members with clinical diagnoses of HAE. The samples underwent genomic DNA extraction and evaluation for purity prior to sequencing. The DNA samples were processed through a semi-automated whole exome library prep pipeline and sequenced. Results: Clinical variant analysis revealed two common benign variants of Summary: Without additional techniques following NGS and MLPA, such as a soft clipping analysis method, many difficult-to-detect large insertions and deletions may go undetected. We propose that a systematic approach to undetected HAE-causing mutation analysis, incorporating soft clipping as part of an overall strategy, would be more effective in identifying a small percentage of causal variants in approximately 5% of C1-esterase inhibitor HAE cases where no mutation is found by standard laboratory procedures, especially when there are high clinical suspicions of a familiar disorder.

Indexed as

c1-inhibitor (C1INH)hereditary angioedema (HAE)multiplex ligation-dependent probe amplification (MLPA)next generation sequencing (NGS)SERPING1soft clipping

Identifiers

PMID40313637
PMCPMC12043597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.